Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Early Bortezomib Following Allogeneic Stem Cell Transplantation (SCT) for Multiple Myeloma To Enhance or Maintain Remission Status.

Nicolaus Kroeger, MD, Tatjana Zabelina, MD, Francis Ayuk, MD, Djordje Atanackovic, MD, Heike Schieder, MD, Helmut Renges, MD, Axel R. Zander, MD

Blood (2005) 106 (11): 2010.

https://doi.org/10.1182/blood.V106.11.2010.2010

Published: 2005

Journal Articles

Allogeneic Stem Cell Transplantation from Unrelated Donors within the Seventh Decade of Life.

Joachim Dahlke, Dr.Med., Tatjana Zabelina, Dr.med., Francis Ayuk, Dr.med., Jens Panse, Dr.med., Heike Schieder, Dr.med., Helmut Renges, Dr.med., Djorde Atanackovic, Dr.med., Christine Wolschke, Dr.med., Axel R. Zander, Nicolaus Kroeger, PD Dr.med

Blood (2005) 106 (11): 2062.

https://doi.org/10.1182/blood.V106.11.2062.2062

Published: 2005

Journal Articles

Serum Free Light Chain [FLC] Assay in Multiple Myeloma Patients Who Achieved Negative Immunofixation after Allogeneic Stem Cell Transplantation.

Ulrike Moesbauer, Heike Schieder, MD, Helmut Renges, MD, Francis Ayuk, MD, Axel Zander, MD, Nicolaus Kröger, MD

Blood (2005) 106 (11): 2023.

https://doi.org/10.1182/blood.V106.11.2023.2023

Published: 2005

Journal Articles

Donor KIR Haplotype Genes Significantly Influence Disease-Free and Overall Survival after Myeloablative Conditioning Followed by In Vivo T-Cell Depleted [ATG] Unrelated Stem Cell Transplantation.

Nicolaus Kroeger, MD, Thomas Binder, MD, PhD, Heike Schieder, MD, Helmut Renges, MD, Francis Ayuk, MD, Christine Wolschke, MD, Thomas H. Eiermann, MD, PhD, Axel Zander, MD

Blood (2005) 106 (11): 2040.

https://doi.org/10.1182/blood.V106.11.2040.2040

Published: 2005

Journal Articles

Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma

Nicolaus Kröger, Avichai Shimoni, Maria Zagrivnaja, Francis Ayuk, Michael Lioznov, Heike Schieder, Helmut Renges, Boris Fehse, Tatjana Zabelina, Arnon Nagler, Axel R. Zander

Blood (2004) 104 (10): 3361–3363.

https://doi.org/10.1182/blood-2004-05-2031

Published: 2004

Journal Articles

Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality

Nicolaus Kröger, Herbert Gottfried Sayer, Rainer Schwerdtfeger, Michael Kiehl, Arnon Nagler, Helmut Renges, Tatjana Zabelina, Boris Fehse, Francis Ayuk, Georg Wittkowsky, Norbert Schmitz, Axel Rolf Zander

Blood (2002) 100 (12): 3919–3924.

https://doi.org/10.1182/blood-2002-04-1150

Published: 2002

Journal Articles

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

Nicolaus Kröger, Rainer Schwerdtfeger, Michael Kiehl, Herbert Gottfried Sayer, Helmut Renges, Tatjana Zabelina, Boris Fehse, Florian Tögel, Georg Wittkowsky, Rolf Kuse, Axel Rolf Zander

Blood (2002) 100 (3): 755–760.

https://doi.org/10.1182/blood-2002-01-0131

Published: 2002

NARROW

Early Bortezomib Following Allogeneic Stem Cell Transplantation (SCT) for Multiple Myeloma To Enhance or Maintain Remission Status.

Allogeneic Stem Cell Transplantation from Unrelated Donors within the Seventh Decade of Life.

Serum Free Light Chain [FLC] Assay in Multiple Myeloma Patients Who Achieved Negative Immunofixation after Allogeneic Stem Cell Transplantation.

Donor KIR Haplotype Genes Significantly Influence Disease-Free and Overall Survival after Myeloablative Conditioning Followed by In Vivo T-Cell Depleted [ATG] Unrelated Stem Cell Transplantation.

Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma

Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Early Bortezomib Following Allogeneic Stem Cell Transplantation (SCT) for Multiple Myeloma To Enhance or Maintain Remission Status.

Allogeneic Stem Cell Transplantation from Unrelated Donors within the Seventh Decade of Life.

Serum Free Light Chain [FLC] Assay in Multiple Myeloma Patients Who Achieved Negative Immunofixation after Allogeneic Stem Cell Transplantation.

Donor KIR Haplotype Genes Significantly Influence Disease-Free and Overall Survival after Myeloablative Conditioning Followed by In Vivo T-Cell Depleted [ATG] Unrelated Stem Cell Transplantation.

Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma

Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only